Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib

Alessandro Gronchi; Sylvie Bonvalot; A. Poveda Velasco; Dusan Kotasek; Piotr Rutkowski; Peter Hohenberger; Elena Fumagalli; Ian Judson; Antoîne Italiano; Hans Gelderblom; Frits van Coevorden; Nicolas Penel; Hans‐Georg Kopp; Florence Duffaud; David Goldstein; Javier Martín‐Broto; Eva Wardelmann; Sandrine Marréaud; B. Mark Smithers; Axel Le Cesne; Facundo Zaffaroni; Saskia Litière; Jean Yves Blay; Paolo G. Casali

doi:10.1001/jamasurg.2020.0397

Related publications

Article2022

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Patrick Schöffski, Suzanne George, Michael C. Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Kelvin Shi, Julie Meade, Rodrigo Ruiz‐Soto, Jean Yves Blay, Margaret von Mehren

Article2019

Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial

Judith S. Hochman, Harmony R. Reynolds, Sripal Bangalore, Sean M. O’Brien, Karen P. Alexander, Roxy Senior, William E. Boden, Gregg W. Stone, Shaun G. Goodman, Renato D. Lópes, José López‐Sendón, Harvey D. White, Aldo Maggioni, Leslee J. Shaw, James K. Min, Michael H. Picard, Daniel S. Berman, Bernard Chaitman, Daniel B. Mark, John A. Spertus, Derek D. Cyr, Balram Bhargava, Witold Rużyłło,

Article2010

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)

Andrew F. Shorr, Jonathan Janes, Antonio Artigas, Jyrki Tenhunen, Duncan Wyncoll, Emmanuelle Mercier, Bruno François, Jean Louis Vincent, Burkhard Vangerow, Darell Heiselman, Amy G Leishman, Yajun Emily Zhu, Konrad Reinhart, for the RESPOND Investigators

Article2025

Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial

Desmond Yip, John Zalcberg, Jean Yves Blay, Mikael Eriksson, David Espinoza, Timothy Price, Sandrine Marréaud, Antoîne Italiano, Neeltje Steeghs, Kjetil Boye, Craig Underhill, Val Gebski, John Simes, Hans Gelderblom, Heikki Joensuu

Article2021

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Stefan Knop, María‐Victoria Mateos, Meletios A Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Ganna Usenko, Luděk Pour, Mark Cook, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung‐Soo Yoon, Genadi Losava, Tomoaki Fujisaki, Mamta Garg, Jianping Wang,